GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma ; volume:13 ; number:1 ; day:10 ; month:12 ; year:2020 ; pages:1-16 ; date:12.2020
Journal of hematology & oncology ; 13, Heft 1 (10.12.2020), 1-16, 12.2020
- Creator
-
Park, Jeong A.
Cheung, Nai-Kong V.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-020-01012-y
- URN
-
urn:nbn:de:101:1-2021011720111361846636
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Park, Jeong A.
- Cheung, Nai-Kong V.
- SpringerLink (Online service)
Other Objects (12)
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
How We Treat HER2-Positive Metastatic Breast Cancer
Novel T Cell-Engaging, Bispecific Antibodies for Depletion of Human Immunodeficiency Virus-Infected Cells
Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization
Bispecific antibodies
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
How We Treat HER2-Positive Metastatic Breast Cancer
Novel T Cell-Engaging, Bispecific Antibodies for Depletion of Human Immunodeficiency Virus-Infected Cells
Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization
Bispecific antibodies
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
How We Treat HER2-Positive Metastatic Breast Cancer
Novel T Cell-Engaging, Bispecific Antibodies for Depletion of Human Immunodeficiency Virus-Infected Cells
Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization